Recurrent Pregnancy Loss (RPL)

Summary

Recurrent pregnancy loss (RPL) is a complex, multifactorial condition affecting 1–2% of women of reproductive age. Despite significant advances in understanding its etiologies—genetic, anatomical, endocrine, immunological, and thrombotic—over half of cases remain unexplained. The emotional and psychological burden on couples is substantial, requiring compassionate multidisciplinary support. Comprehensive evaluation and targeted management of identified causes are essential. Importantly, with appropriate treatment and counselling, 50–70% of women with RPL achieve a successful live birth in the next pregnancy.

Definition & Epidemiology

Recurrent pregnancy loss (RPL), also referred to as recurrent miscarriage or habitual abortion, is classically defined as three or more consecutive pregnancy losses before 20–24 weeks of gestation. The Royal College of Obstetricians and Gynaecologists (RCOG) defines it as three or more miscarriages before 24 weeks, although in clinical practice, some guidelines recommend evaluation after two losses if there are concerning features (e.g., advanced maternal age, prior investigation results).

RPL affects approximately 1–2% of women of reproductive age, though the prevalence may be higher if including two-loss cohorts. The incidence rises with maternal age and prior miscarriage number. RPL carries significant psychological and emotional burden, requiring sensitive counselling, multidisciplinary support, and realistic prognostication. Many couples experience depression, anxiety, and relationship strain; integrated mental-health support is essential to holistic care.

Etiology & Risk Factors

RPL is multifactorial, with an identifiable cause in only 40–50% of cases. More than half of affected couples receive no clear explanation for their losses, a sobering reality that frames the need for supportive and reassuring counselling.

1. Genetic Factors

• Embryonic chromosomal abnormalities account for 30–57% of miscarriages (mainly trisomies 16, 22, 21, 13). Maternal age is a strong risk factor; risk rises from 11% at age 20 to >50% after 40 and >90% above 45.
• Parental chromosomal rearrangements are present in 2–5% of RPL couples, usually balanced reciprocal or Robertsonian translocations. These lead to unbalanced conceptions with 50% risk of aneuploidy per pregnancy.

2. Anatomical Abnormalities

Congenital uterine malformations (resulting from Müllerian duct abnormalities) account for ~12% of RPL cases. The three most clinically tested anomalies are:

• Septate uterus (most common cause of uterine anomaly–related RPL) — a longitudinal septum divides the cavity due to incomplete involution. The septum is poorly vascularized, predisposing to early loss. Hysteroscopic metroplasty improves live birth rates by 10–15%.
• Bicornuate uterus — two separate uterine horns from incomplete lateral fusion. Associated with preterm labour and intrauterine growth restriction; limited evidence for surgical benefit.
• Arcuate uterus — a mild fundal indentation; minimal impact on fertility; rarely requires intervention.

Acquired anatomical lesions include intrauterine adhesions (Asherman's syndrome) from dilation and curettage or uterine instrumentation, which can cause mid-trimester loss due to reduced endometrial receptivity, and submucosal fibroids distorting the cavity. Diagnostic hysteroscopy with lysis of adhesions and fibroid resection is therapeutic.

3. Antiphospholipid Syndrome (APS)

4. Endocrine and Metabolic Disorders

• Uncontrolled diabetes mellitus and thyroid disease increase miscarriage risk significantly. Target HbA1c <6.5% pre-conception and TSH 0.5–2.5 mIU/L; optimize prior to pregnancy.
• Polycystic ovarian syndrome (PCOS) is associated with RPL, likely due to insulin resistance, elevated luteinizing hormone (LH), and hyperandrogenism. Weight loss of 5–10% body weight improves outcomes; inositol or metformin may be indicated.
• Progesterone deficiency and hyperprolactinemia remain controversial etiologies. Some clinicians measure luteal-phase progesterone or serial hCG doubling rates, though evidence for progesterone supplementation beyond luteal support is limited.

5. Inherited Thrombophilias

• Factor V Leiden (FVL) — most common heritable thrombophilia (5% of Caucasians heterozygous); homozygous FVL carries higher risk.
• Prothrombin gene mutation (G20210A) — second most common; often coinherited with FVL as a compound heterozygote, conferring higher thrombotic risk.
• Protein C or S deficiency, Antithrombin III deficiency — rarer but strongly associated with recurrent second-trimester losses due to placental thrombosis and infarction.

Note: The role of thrombophilia screening in unexplained RPL remains debated; current guidelines suggest screening in specific contexts (e.g., family history of thrombosis, prior second-trimester loss).

Maternal Risk Factors (Merged)

• Maternal age >40 — miscarriage risk exceeds 50%; age >45 carries >90% risk. Parental age also contributes; paternal age >40 associated with increased aneuploidy.
• Lifestyle factors — smoking, alcohol use (>2 units daily), high caffeine intake (>200 mg daily), psychological stress, and abnormal BMI (both <18.5 and >30) all increase loss rates.
• Number of prior losses — risk increases with successive losses; after three consecutive losses, the risk of a fourth exceeds 40% (though counselling should emphasize the ~50–70% chance of live birth in the next pregnancy).

Clinical Evaluation & Investigations

All women presenting with RPL should undergo a systematic, cause-directed evaluation. The investigation strategy is guided by the suspected etiology, maternal age, and prior loss timing (early vs. mid-trimester).

History and Examination

• Detailed medical, obstetric, and family history, including prior loss gestations, delivery records, karyotypes (if available), and screening results.
• Thorough pelvic examination and assessment for clinical stigmata of systemic disease (e.g., lupus rash, weight changes, thyroid nodules).
• Enquire about lifestyle factors: smoking, alcohol, caffeine, stress, trauma, and partner/paternal factors (age, occupational exposures).

Applying Classification Table — Diagnostic Investigations by Suspected Etiology

Management Protocols

Management of RPL is cause-specific and multidisciplinary. When an etiology is identified, targeted intervention can significantly improve live birth rates. For unexplained RPL, supportive care, psychological counselling, and reassurance form the foundation of management.

Cervical Cerclage — Technical Notes

Indications: Documented cervical incompetence (transabdominal or transvaginal cervical length <25 mm at 16–24 weeks) or a prior mid-trimester loss with sudden painless dilatation or vaginal bleeding in the absence of infection or uterine contractions.

Timing: Place at 12–14 weeks of gestation. McDonald technique (encircles the cervix submucosal, higher in the cervical stroma, faster, reversible) is most common. Shirodkar technique (a purse-string suture placed higher, more invasive, lower removal risk) is reserved for recurrent cerclage failure.

Adjunctive therapy: Vaginal progesterone (micronized progesterone 200 mg or 17-alpha-hydroxyprogesterone caproate 250 mg) or pessary placement may improve outcomes further, especially if cervical length 20–25 mm.

Cerclage removal: Remove at 36–37 weeks to permit vaginal delivery. Elective cerclage removal before term labour avoids cervical trauma and uterine rupture from unplanned labouring with cerclage in situ.

Unexplained RPL & Prognosis

Unexplained RPL

More than 50% of RPL cases have no identifiable cause despite comprehensive investigation. This absence of explanation presents both a clinical and psychological challenge. It is crucial to reframe this uncertainty positively: unexplained RPL does NOT mean a worse prognosis—it simply reflects the limitations of current diagnostic testing.

Management approach:

• Supportive care and counselling — Detailed discussion of the ~50–70% live birth rate with the next pregnancy, regardless of treatment. Many couples benefit from the reassurance that even without intervention, over half will achieve success.
• Controversial interventions — Empirical low-dose aspirin (75–150 mg daily from pre-conception) is sometimes offered, though evidence remains mixed and conflicting. Empirical anticoagulation or immunosuppression is not recommended outside of proven etiologies (e.g., APS, thrombophilia).
• Psychological support — Referral to counselling, support groups (many nations have RPL networks), couples' therapy, and discussion of alternative family-building options (adoption, donor gametes) if losses continue.
• Lifestyle optimisation — Smoking cessation, reduced caffeine and alcohol, weight management, stress reduction, regular exercise, and folic acid supplementation (5 mg daily) are universally recommended.

Prognosis

Even without treatment, the prognosis for women with RPL is surprisingly optimistic:

• Untreated cohorts show live birth rates of 50–70% with the next spontaneous pregnancy, suggesting that many RPL patients will achieve success without intervention.
• Prognosis depends on:
  • Maternal age — Age >40 carries higher aneuploidy risk and lower live birth rates; age >45 dramatically worsens outlook.
  • Number and timing of prior losses — After three consecutive losses, the risk of a fourth exceeds 40%, but the cumulative live birth rate remains ~60% with supportive management.
  • Underlying etiology — Causes such as APS, anatomical anomalies, and endocrine disorders have specific treatments that markedly improve outcomes. Genetic translocations have more guarded prognosis (10–20% natural conception live birth rate) but excellent outcomes with IVF + PGT-A.
• With treatment — Women with APS treated with aspirin and heparin achieve 50–80% live birth rates (up from ~10% untreated). Surgical correction of septate uterus improves rates by 10–15%. Cervical cerclage reduces preterm birth and improves viability in women with documented incompetence.
• Counselling message — Frame RPL as a challenge that, in the majority of cases, will ultimately resolve with time, supportive management, psychological care, and identification and treatment of any modifiable risk factors. The emotional resilience of couples who continue trying after RPL is remarkable, and outcomes often justify their persistence.

Key Points for Exams – نقاط مهمة للامتحانات

High-Yield Summary for Board Exams

• Definition: RPL = ≥3 consecutive pregnancy losses before 20–24 weeks. Affects 1–2% of reproductive-age women; >50% remain unexplained.
• GAITER mnemonic: Genetic, Anatomical, Immunologic (APS), Thrombophilic, Endocrine, Risk factors. Use to recall the major etiologies systematically.
• Antiphospholipid Syndrome (15% of RPL):
  • Diagnostic criteria: Persistent antiphospholipid antibodies (LA, aCL, or anti-β2GPI) ≥12 weeks apart PLUS clinical features (recurrent loss or thrombosis).
  • Untreated live birth rate ~10%; treated (aspirin + heparin) ~50–80%.
  • Do NOT give anticoagulation for unexplained RPL without proven APS.
• Septate uterus (most common anomaly-related RPL): Hysteroscopic metroplasty pre-conception improves live birth by 10–15%. Can be differentiated from bicornuate on 3D ultrasound or MRI.
• Cervical incompetence (second-trimester pathognomonic finding): Painless cervical dilatation at 16–24 weeks. Diagnosed by cervical length <25 mm on transvaginal US. Managed with cerclage at 12–14 weeks ± vaginal progesterone. Removes cerclage at 36–37 weeks.
• Maternal age impact: Miscarriage risk rises from 11% at age 20 to >50% after age 40, and >90% above 45 (mostly aneuploidy).
• Thrombophilias: Factor V Leiden and prothrombin G20210A are most common. Second-trimester losses more common with heritable thrombophilia due to placental infarction. Screening indicated if prior thrombosis or strong family history.
• Parental chromosomal rearrangement (2–5% of RPL): Balanced translocation carrier is clinically normal but has 50% risk of aneuploidy per pregnancy. Offer genetic counselling and consider PGT-A with IVF.
• Endocrine optimisation pre-conception: TSH <2.5 mIU/L, HbA1c <6.5%, consider levothyroxine for subclinical hypothyroidism in RPL context.
• Unexplained RPL (~50%): Prognosis is NOT grim—live birth rate 50–70% with next pregnancy even without treatment. Emphasise supportive care, psychological counselling, and lifestyle modification over empirical medications.
• Investigation sequence: Start with karyotype (parental), pelvic ultrasound, antiphospholipid antibodies. Escalate imaging (3D US, HSG, hysteroscopy) if anatomical suspicion. Thrombophilia screen reserved for high-risk phenotype (family history, prior thrombosis).
• Aspirin + heparin only for proven APS or high-risk thrombophilia in pregnancy; NOT empirical therapy for unexplained RPL.